A Study of the Combination of Anti-PD-1 AK105 and Anlotinib in First-line Hepatocellular Carcinoma (HCC)

Clinical trial NCT04172571 · COMPLETED

Trial details

NCT number: NCT04172571
Sponsor: Akeso
Status: COMPLETED
Phase: Phase 2
Study type: INTERVENTIONAL

Hepatocellular Carcinoma

Start date: 2018-11-22
Primary completion: 2022-06-01
Enrollment: 31

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.